Evotec SE
EVT: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€6.40 | Vcntp | Jmfzzgl |
Demand for Biologics CDMO Services Continues to Spur Growth, as Evotec Focuses on Profitability
Business Strategy and Outlook
Evotec is a drug discovery partnership firm that has a contract development and manufacturing organization, or CDMO, business, in addition to an innovative drug development program focused on collaboration with clients. The firm offers services across a variety of therapeutic areas and serves a diverse client base of large and midsize pharmaceutical and biotechnology companies. Following a recent period of investment that has weighed on returns, Evotec appears well positioned to mature and stabilize its business as its strategic growth initiatives materialize.